The Biden administration has reformed Medicare, gone after bogus drug patents and pushed pharmaceutical companies to reduce ...

Generic inhalers can cost as little as $30 ... cap applies to both of those products and the rest of its asthma and COPD ...

Not studied in patients with acutely deteriorating asthma or COPD. Immediately reevaluate patients and their treatment regimen if they require an increased use of inhaled, short-acting beta2 ...

The UK pharma’s ageing Advair inhaler, still a mainstay of GSK's respiratory portfolio, is threatened by generic competition ... obstruction in patients with COPD, including chronic bronchitis ...

Do not initiate in acutely deteriorating COPD. Not for relief of acute symptoms. Prescribe a short-acting inhaled β 2-agonist for acute symptoms; monitor for increased need. Do not exceed ...

A new analysis that compares two common inhalers for patients suffering from chronic obstructive pulmonary disease (COPD) finds that one reduces respiratory-related hospitalizations and ...

Patients with asthma and COPD routinely switch from pressurized metered-dose inhalers to dry powder inhalers and vice versa.

Teva has launched new digital inhaler ... generic version of GlaxoSmithKline’s blockbuster inhaler Advair (fluticasone+salmeterol). The competition for the product approved in asthma and COPD ...

Caroline Quill, MD, of the University of Rochester Medical Center, highlighted the potential of artificial intelligence (AI) ...

Inhalers prescribed to Centers for Medicare & Medicaid Services (CMS) beneficiaries for asthma and chronic obstructive ...

Two posters presented at the CHEST 2024 annual meeting underscore the importance of early identification and treatment of ...

While people with asthma or chronic obstructive pulmonary disease (COPD) can experience worse symptoms due to climate change, many of the medications they’re prescribed also contribute to ...